From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Clinical data
Routes of
oral, insufflation, vaporization, IV
Legal status
Legal status
PubChem CID
Chemical and physical data
Molar mass233.305 g/mol g·mol−1
3D model (JSmol)
ChiralityRacemic mixture

4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP) is a stimulant designer drug of the pyrrolidinophenone class. It has the potential to produce euphoria,[citation needed] an effect shared with other classical stimulants.

Recreational use[edit]

MOPPP use is infrequent when compared to other amphetamines or stimulants used recreationally, such as meth, cocaine, or speed. It first arose as a designer drug in Germany in the late 1990s and early 2000s,[1][2][3] along with a number of other derivatives but never gained the international popularity[4][5] that other drugs in its family of pyrrolidinophenone derivatives had (such as α-PPP and MDPV).

While the recent trend of selling stimulants through false labeling (i.e., bath salts) has gained notoriety, using MDPV as its main ingredient, this has not been the case with MOPPP, despite its similar potential for abuse.[6]


MOPPP is structurally related to α-PPP in the same way that PMA is related to amphetamine: a methoxy group has been added to the 4-position on the phenyl ring.

Comparison of similar molecular structure


MOPPP appears to be metabolized within the liver chiefly by the enzyme CYP2D6.[2]

See also[edit]


  1. ^ Springer, D.; Fritschi, G.; Maurer, H. H. (2003). "Metabolism and toxicological detection of the new designer drug 4′-methoxy-α-pyrrolidinopropiophenone studied in rat urine using gas chromatography–mass spectrometry". Journal of Chromatography B. 793 (2): 331–42. doi:10.1016/S1570-0232(03)00334-9. PMID 12906908.
  2. ^ a b Springer, D.; Staack, R. F.; Paul, L. D.; Kraemer, T.; Maurer, H. H. (2003). "Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy-α-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes". Xenobiotica. 33 (10): 989–998. doi:10.1080/00498250310001602775. PMID 14555336.
  3. ^ Springer, D.; Fritschi, G.; Maurer, H. H. (2003). "Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography B. 796 (2): 253–66. doi:10.1016/j.jchromb.2003.07.008. PMID 14581066.
  4. ^ Maurer, H. H.; Kraemer, T.; Springer, D.; Staack, R. F. (2004). "Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types". Therapeutic Drug Monitoring. 26 (2): 127–131. doi:10.1097/00007691-200404000-00007. PMID 15228152.
  5. ^ Staack, R.; Maurer, H. (2005). "Metabolism of Designer Drugs of Abuse". Current Drug Metabolism. 6 (3): 259–274. doi:10.2174/1389200054021825. PMID 15975043.
  6. ^ "MDPV Bath Salts Drug Over The Counter". Healthbodydaily.com. 8 March 2011. Archived from the original on 10 March 2011.